Literature DB >> 6436394

Efficacy of pyrazolopyrimidine ribonucleosides against Trypanosoma cruzi: studies in vitro and in vivo with sensitive and resistant strains.

R L Berens, J J Marr, D L Looker, D J Nelson, S W LaFon.   

Abstract

Strains of Trypanosoma cruzi differ in their susceptibilities to and metabolism of pyrazolopyrimidines. Allopurinol riboside can control but not eliminate infections with a sensitive strain in both tissue culture and mice. Formycin B, which proved to be greater than 10-fold more effective on a weight basis, showed a similar strain specificity but could eliminate an infection with a sensitive strain from tissue culture. However, this drug, unlike allopurinol riboside, was converted to toxic analogues of adenosine mono-, di-, and triphosphate by uninfected tissue culture cells. Thiopurinol and its riboside were effective against all strains unless culture was performed in purine-defined medium. Thus formycin B and allopurinol riboside appear to be good models for the design of antitrypanosomal agents. Suitable modification of the molecule may provide an effective chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436394     DOI: 10.1093/infdis/150.4.602

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Activity of P536, a UDP-glucose analog, against Trypanosoma cruzi.

Authors:  A Alcina; M Fresno; B Alarcón
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

2.  Molecular biology studies of tubercidin resistance in Trypanosoma cruzi.

Authors:  T Nozaki; J A Dvorak
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

3.  Inosine analogs as chemotherapeutic agents for African trypanosomes: metabolism in trypanosomes and efficacy in tissue culture.

Authors:  W R Fish; J J Marr; R L Berens; D L Looker; D J Nelson; S W LaFon; A E Balber
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.